Tauziède-Espariat Arnault, Dangouloff-Ros Volodia, Sievers Philipp, Duchesne Mathilde, Siegfried Aurore, Nicaise Yvan, Boddaert Nathalie, Hasty Lauren, Métais Alice, Ngo Carine, le Loarer François, Bouvier Corinne, Fontaine Alix, Rousseau Audrey, Marguet Florent, Beccaria Kévin, Blauwblomme Thomas, Uro-Coste Emmanuelle, Varlet Pascale
Department of Neuropathology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France.
Acta Neuropathol Commun. 2025 May 24;13(1):114. doi: 10.1186/s40478-025-02037-5.
The neuroepithelial tumor, PATZ1-fused (NET-PATZ1), has been recently isolated as a distinct methylation class by DNA-methylation profiling and is characterized by recurrent PATZ1 fusions, in association with the EWSR1 or MN1 genes and a chromosome 22 chromothripsis. The clinical phenotype is mainly pediatric and features circumscribed supratentorial tumors. However, the histopathology is vastly heterogeneous (glial, glioneuronal, sarcomatous, multiphenotypic) and a cell of origin has not yet been identified, explaining the previsionary imprecise terminology of "NET". Moreover, extra-central nervous system (CNS) sarcomas also harboring the EWSR1::PATZ1 fusion have been reported and added to the current World Health Organization (WHO) Classification of Soft Tissue and Bone Tumors, in the chapter on undifferentiated small round cell sarcomas. However, their relationship to their CNS counterparts has not yet been studied. Herein, we analyzed a cohort of twelve CNS tumors with PATZ1 fusions in terms of clinical presentation, radiology, histopathology, immunohistochemistry, ultrastructure and DNA-methylation profiling and compared them to five extra-CNS sarcomas-PATZ1. Based on the reported GATA2 overexpression in NET-PATZ1, we also studied the potential interest of GATA2 immunoexpression as a diagnostic tool. We confirmed their distinct molecular characteristics and clinical phenotype but evidenced a morphological intratumoral heterogeneity with three recurrent morphological patterns (oligodendroglial-like, pleomorphic xanthoastrocytoma-like and spindle cells). Despite the unusual spindle and proliferative component in a CD34 + glioneuronal tumor (using electronic microscopy), these tumors present a favorable prognosis. Their histopathological features were all clearly distinct from their soft tissue counterparts. GATA2 immunostaining is highly specific for CNS tumors PATZ1-fused, but its sensitivity is perfectible and further studies are needed to confirm its use as a diagnostic tool. To conclude, our work highlights that CNS tumors, PATZ1-fused seem to represent a novel pediatric glioneuronal tumor type exhibiting a polymorphous morphology and provides new support for its addition as a provisional emerging pediatric circumscribed glioneuronal tumor type, low grade.
神经上皮肿瘤,PATZ1融合型(NET-PATZ1),最近通过DNA甲基化分析被分离为一种独特的甲基化类型,其特征为反复出现的PATZ1融合,与EWSR1或MN1基因以及22号染色体碎裂相关。临床表型主要见于儿童,以幕上局限性肿瘤为特征。然而,组织病理学表现极为异质性(胶质、胶质神经元、肉瘤样、多表型),且起源细胞尚未明确,这就解释了“NET”这一前瞻性不精确术语的由来。此外,还报道了中枢神经系统(CNS)外的肉瘤也存在EWSR1::PATZ1融合,并被纳入了世界卫生组织(WHO)软组织和骨肿瘤分类中未分化小圆细胞肉瘤章节。然而,它们与CNS对应肿瘤的关系尚未得到研究。在此,我们分析了一组12例具有PATZ1融合的CNS肿瘤的临床表现、放射学、组织病理学、免疫组织化学、超微结构和DNA甲基化分析,并将其与5例CNS外肉瘤-PATZ1进行比较。基于报道的NET-PATZ1中GATA2过表达,我们还研究了GATA2免疫表达作为诊断工具的潜在价值。我们证实了它们独特的分子特征和临床表型,但也发现肿瘤内存在三种反复出现的形态学模式(少突胶质细胞瘤样、多形性黄色星形细胞瘤样和梭形细胞)的形态学异质性。尽管在一个CD34 + 胶质神经元肿瘤中存在不寻常的梭形和增殖成分(使用电子显微镜观察),但这些肿瘤预后良好。它们的组织病理学特征与软组织对应肿瘤明显不同。GATA2免疫染色对CNS肿瘤PATZ1融合型具有高度特异性,但其敏感性仍有待完善,需要进一步研究以证实其作为诊断工具的用途。总之,我们的研究强调,PATZ1融合型CNS肿瘤似乎代表了一种新型儿童胶质神经元肿瘤类型,具有多形性形态,并为将其作为一种临时出现的低级别儿童局限性胶质神经元肿瘤类型增加提供了新的支持。